Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Aug 1;1(5):699-716.

2.

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Sep 1;1(6):894-907.

3.

Trial Watch: Toll-like receptor agonists for cancer therapy.

Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Aug 1;2(8):e25238. Epub 2013 Jun 10. Review.

4.

Trial Watch: Toll-like receptor agonists in oncological indications.

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Aug 1;3:e29179. eCollection 2014.

5.

Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan.

Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, Kawata T, Azuma I, Toyoshima K, Seya T.

Infect Immun. 2003 Aug;71(8):4238-49.

6.

Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guérin by Flt3-ligand generated dendritic cells.

von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H, Sparwasser T.

Immunobiology. 2006;211(6-8):557-65. Epub 2006 Jul 5.

PMID:
16920494
7.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
8.

Role of apoptosis-regulating signal kinase 1 in innate immune responses by Mycobacterium bovis bacillus Calmette-Guérin.

Yuk JM, Shin DM, Yang CS, Kim KH, An SJ, Rho J, Park JK, Jo EK.

Immunol Cell Biol. 2009 Jan;87(1):100-7. doi: 10.1038/icb.2008.74. Epub 2008 Oct 14.

PMID:
18852704
9.
10.

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Sep 2;5(3):e1088631. eCollection 2016 Mar. Review.

11.

Toll-like receptor agonists in cancer therapy.

Adams S.

Immunotherapy. 2009 Nov;1(6):949-64. doi: 10.2217/imt.09.70. Review.

12.

Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.

Simmons DP, Canaday DH, Liu Y, Li Q, Huang A, Boom WH, Harding CV.

J Immunol. 2010 Aug 15;185(4):2405-15. doi: 10.4049/jimmunol.0904005. Epub 2010 Jul 21.

13.

TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG.

Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, Vogel SN, Fenton MJ.

J Leukoc Biol. 2003 Aug;74(2):277-86.

PMID:
12885945
14.

[Innate immunity: structure and function of TLRs].

Delneste Y, Beauvillain C, Jeannin P.

Med Sci (Paris). 2007 Jan;23(1):67-73. French.

16.

Toll-like receptors as adjuvant receptors.

Kaisho T, Akira S.

Biochim Biophys Acta. 2002 Feb 13;1589(1):1-13. Review.

17.

TLR Agonists as Adjuvants for Cancer Vaccines.

Li JK, Balic JJ, Yu L, Jenkins B.

Adv Exp Med Biol. 2017;1024:195-212. doi: 10.1007/978-981-10-5987-2_9.

PMID:
28921471
18.

Determinant role for Toll-like receptor signalling in acute mycobacterial infection in the respiratory tract.

Tjärnlund A, Guirado E, Julián E, Cardona PJ, Fernández C.

Microbes Infect. 2006 Jun;8(7):1790-800. Epub 2006 Apr 27.

PMID:
16815067
19.

Regulation of innate immune responses by Toll-like receptors.

Takeda K, Akira S.

Jpn J Infect Dis. 2001 Dec;54(6):209-19. Review.

PMID:
11862002
20.

Supplemental Content

Support Center